BPC-157/TB-500
500 mcg · Daily
Robert
Founder, F*CK Getting Old — independent researcher, not a medical professional.
Last reviewed · 3 cited sources
Evidence
- Human Studies
- 3
- Animal Studies
- 45
- Clinical Status
- Research
- Confidence
- Low
- Long-Term Safety
- Unknown — no long-term human safety data published
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
BPC-157 is a synthetic fragment derived from a protein found in gastric juice, studied for effects on angiogenesis and tissue repair signaling. TB-500 is a synthetic fragment of thymosin beta-4, studied for actin regulation involved in cell migration and wound healing.
Common Protocols
- 250–500 mcg once or twice daily, injected near the site of injury or subcutaneously
- Typical research cycles run 4–8 weeks
Side Effects
- Injection site irritation
- Mild fatigue reported anecdotally
- Limited formal adverse-event data in humans
Interactions
- Little formal drug-interaction research exists; caution advised when combined with other experimental compounds
Practical Details
- Cost
- $$
- Typical Vial Size
- 5 mg
- Storage
- Refrigerate after reconstitution; use within 2–4 weeks for best stability
Key Studies & Reviews
- Vasireddi N et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. PMID 40756949.
- Hannappel E (2007). beta-Thymosins. Ann N Y Acad Sci. PMID 17468232.
- Mendias CL, Awan TM (2026). Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. PMID 41966639.
Search the Research
BPC-157/TB-500 FAQ
What is the typical BPC-157/TB-500 dosage?
Commonly reported protocols: 250–500 mcg once or twice daily, injected near the site of injury or subcutaneously; Typical research cycles run 4–8 weeks. Our reference entry uses 500 mcg, Daily. These reflect protocols reported in research and user communities, not a medical recommendation — dosing should be decided with a clinician.
What are the side effects of BPC-157/TB-500?
Reported side effects include: Injection site irritation; Mild fatigue reported anecdotally; Limited formal adverse-event data in humans.
Is BPC-157/TB-500 FDA approved?
BPC-157/TB-500 is not FDA approved for human use and is generally sold as a research chemical, so purity and dosing are not regulated.
How much research is there on BPC-157/TB-500?
Our evidence profile counts roughly 3 human and 45 animal studies, with low overall confidence. Long-term safety: Unknown — no long-term human safety data published.
Does BPC-157/TB-500 interact with other drugs or supplements?
Little formal drug-interaction research exists; caution advised when combined with other experimental compounds.
How do I reconstitute BPC-157/TB-500?
A common setup is a 5 mg vial mixed with 2 mL of bacteriostatic water, which puts a 500 mcg dose at about 20 units on a U-100 insulin syringe. Use the reconstitution calculator with your own vial and dose to get exact numbers. Storage: Refrigerate after reconstitution; use within 2–4 weeks for best stability.
Compare
Related compounds
0.5mg BPC-157 + 0.5mg TB-500 combined, separate syringe from NAD+